Met receptor is a promising therapeutic target in multiple cancer types [35], especially non-small cell lung cancer, in which Met overexpression has recently been shown to contribute to EGFR TKI resistance, including resistance to gefitinib [18] and erlotinib [36]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.